The Expert Angle
Medlior is a well-known and trusted industry leader.
Our team is dedicated to delivering high-quality research that provides a solid basis for informed decision-making.
Medlior’s Expert Angle offers the inside track on new studies, industry hot topics, and what you need to know in the fast-paced world of clinical research, all from the point of view of the Medlior team of experts. From the latest topics and trends to the foundations of health and medical research, Medlior explores topics relevant to clients and the world.
The Health Research Ethics Board of Alberta – Community Health Committee: a valuable partner for research success
The Health Research Ethics Board of Alberta - Community Health Committee (HREBA-CHC) provides tremendous value for community-based research organizations in Alberta. Over the past four years, Medlior’s Calgary-based research team has conducted ten industry-sponsored Real World Evidence ...
Case Study: Atherosclerotic Cardiovascular Disease
Medlior’s RWE study examining the treatment landscape and clinical outcomes for patients with atherosclerotic cardiovascular disease in Alberta Introduction Medlior Health Outcomes Research Ltd. was engaged by Amgen Inc., one of the world’s leading biopharmaceutical companies, to examine ...
Network Meta-Analysis of First-line treatments for non-small cell lung cancer – ISPOR 2020
Medlior presented exciting new results from a network meta-analysis (NMA) project sponsored by Pfizer Inc., at the Virtual ISPOR 2020 Annual Meeting. This poster presentation compared the effects of first-line treatments for non-small cell lung (NSCLC). A brief overview of the presentation is ...
EAHAD 2020: Haemophilia-A SLR Project
Haemophilia-A (HA) is a congenital x‐linked bleeding disorder caused by a deficiency of blood coagulation factor VIII (FVIII), occurring in approximately one in every 5000 male live births. HA is currently without a cure and therefore requires life-long monitoring and treatment of potentially life‐threatening bleeding events. Existing treatments for the management of this disorder include the use of plasma‐derived factor concentrates, recombinant factor concentrates, and more recently, monoclonal antibodies (e.g. emicizumab).
DLBCL Environmental Scan
Understanding and identifying the unmet need of aggressive B-cell lymphomas is critical for positioning new therapies Aggressive B-cell lymphomas are a subset of non-Hodgkin’s lymphoma (NHL) that encompass a number of neoplasms that include both precursor lymphoid neoplasms and mature ...
Case Study: Multiple Myeloma
Medlior Health Outcomes Research was engaged by Celgene Canada (now a subsidiary of Bristol-Myers Squibb Company) to examine the treatment landscape for patients with multiple myeloma (MM) and the effects of lenalidomide (REVLMID®) as an immunomodulatory imide drug for both newly-diagnosed MM patients and relapsed/refractory MM patients.
Lipid-lowering Therapy Patterns and Low-density Lipoprotein-Cholesterol Management Among Patients with Acute Myocardial Infarction in Alberta, Canada
Medlior’s presentation focuses on a real-world evidence study sponsored by Amgen Inc. examining the management of patients with an acute myocardial infarction (AMI) in Alberta, Canada. AMI is a leader in disease burden and death worldwide. In order to combat AMI, modifiable factors that lower cholesterol, specifically low-density lipoprotein-cholesterol (LDL-C) are needed. Therapies designed to lower LDL-C, such as statins, also called lipid lowering therapies (LLT), are therefore important to understand the patterns of use and to what extent LDL-C is lowered. Medlior’s study utilized health system data to explore the patterns of LLT and the management of LDL-C levels in patients who experienced AMI.
Canadian real-world evidence on epidemiology, outcomes and economics of moderate-to-severe osteoarthritis
A systematic literature review
Osteoarthritis (OA) is a chronic joint disease that leads to a loss of articular cartilage, resulting in painful bone-on-bone contact. Females have a higher risk of developing OA compared to males, and obese individuals are three times more likely to develop OA. ...
Coronavirus background and key questions
As the COVID-19 virus spreads, world governments implement control strategies
This article is about an emerging and rapidly evolving public health crisis. Case and death counts change daily. If you’re interested in learning the very latest information please consult the World Health ...
Medlior partners with Calgary Universities for proof-of-concept study
Study on natural language processing and machine learning to develop oncology decision aid for multiple myeloma in Alberta
In Canada, approximately 2,900 people were diagnosed with multiple myeloma in 2017. Unique, targeted therapies are currently in development for multiple myeloma and will ...
Industry Predictions for 2020
Medlior is looking forward to a year of innovation in health outcomes research with Real World Evidence leading the way. See our predictions for 2020.
Looking Back on 2019
2019 has proven to be a great year for Medlior, the healthcare industry and Real World Evidence. Read our wrap on the last year here.
